Several PD-(L)1 inhibitors have been approved or are in development for the treatment of NSCLC, including pembrolizumab, dostarlimab, nivolumab, and atezolizumab, and have shown promising efficacy and tolerable safety profiles in patients with advanced/metastatic NSCLC5–8. This evidence concerns the gene CD274 and non-small cell lung carcinoma.